Targeting TNF for Treatment of Cancer and Autoimmunity

  • Gautam Sethi
  • Bokyung Sung
  • Ajaikumar B. Kunnumakkara
  • Bharat B. Aggarwal
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 647)


Tumor necrosis factor-α (TNF-α) was first isolated two decades ago as a macrophageproduced protein that can effectively kill tumor cells. TNF-α is also an essential component of the immune system and is required for hematopoiesis, for protection from bacterial infection and for immune cell-mediated cytotoxicity. Extensive research, however, has revealed that TNF-α is one of the major players in tumor initiation, proliferation, invasion, angiogenesis and metastasis. The proinflammatory activities link TNF-α with a wide variety of autoimmune diseases, including psoriasis, inflammatory bowel disease, rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, diabetes and ankylosing spondylitis. Systemic inhibitors of TNF such as etanercept (Enbrel) (a soluble TNF receptor) and infliximab (Remicade) and adalimumab (Humira) (anti-TNF antibodies) have been approved for the treatment inflammatory bowel disease, psoriasis and rheumatoid arthritis. These drugs, however, exhibit severe side effects and are expensive. Hence orally active blockers of TNF-α that are safe, efficacious and inexpensive are urgently needed. Numerous products from fruits, vegetable and traditional medicinal plants have been described which can suppress TNF expression and TNF signaling but their clinical potential is yet uncertain.


Rheumatoid Arthritis Multiple Sclerosis Systemic Lupus Erythematosus Tumor Necrosis Factor Ankylose Spondylitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pennica D, Nedwin GE, Hayflick JS et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312:724–729.PubMedCrossRefGoogle Scholar
  2. 2.
    Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3:745–756.PubMedCrossRefGoogle Scholar
  3. 3.
    Kurzrock R, Rosenblum MG, Sherwin SA et al. Pharmacokinetics, single-dose tolerance and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res 1985; 45:2866–2872.PubMedGoogle Scholar
  4. 4.
    Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869–871.PubMedCrossRefGoogle Scholar
  5. 5.
    Aggarwal BB, Shishodia S, Ashikawa K et al. The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Curr Drug Targets Inflamm Allergy 2002; 1:327–341.PubMedCrossRefGoogle Scholar
  6. 6.
    Nagata S and Golstein P. The Fas death factor. Science 1995; 267:1449–1456.PubMedCrossRefGoogle Scholar
  7. 7.
    Darnay BG Aggarwal BB. Early events in TNF signaling: a story of associations and dissociations. J Leukoc Biol 1997; 61:559–566.PubMedGoogle Scholar
  8. 8.
    Bhardwaj A and Aggarwal BB. Receptor-mediated choreography of life and death. J Clin Immunol 2003; 23:317–332.PubMedCrossRefGoogle Scholar
  9. 9.
    Aggarwal BB and Takada Y. Pro-apototic and anti-apoptotic effects of tumor necrosis factor in tumor cells. Role of nuclear transcription factor NF-kappaB. Cancer Treat Res 2005; 126:103–127.PubMedCrossRefGoogle Scholar
  10. 10.
    Mukhopadhyay A, Suttles J, Stout RD et al. Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligand-mediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages. J Biol Chem 2001; 276:31906–31912.PubMedCrossRefGoogle Scholar
  11. 11.
    Haridas V, Darnay BG, Natarajan K et al. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation and c-Jun kinase activation. J Immunol 1998; 160:3152–3162.PubMedGoogle Scholar
  12. 12.
    Pasparakis M, Alexopoulou L, Episkopou V et al. Immune and inflammatory responses in TNF-alpha-deficient mice: a critical requirement for TNF-alpha in the formation of primary B-cell follicles, follicular dendritic cell networks and germinal centers and in the maturation of the humoral immune response. J Exp Med 1996; 184:1397–1411.PubMedCrossRefGoogle Scholar
  13. 13.
    Marino MW, Dunn A, Grail D et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997; 94:8093–8098.PubMedCrossRefGoogle Scholar
  14. 14.
    Moore RJ, Owens DM, Stamp G et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5:828–831.PubMedCrossRefGoogle Scholar
  15. 15.
    Rothe J, Lesslauer W, Lotscher H et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993; 364:798–802.PubMedCrossRefGoogle Scholar
  16. 16.
    Erickson SL, de Sauvage FJ, Kikly K et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994; 372:560–563.PubMedCrossRefGoogle Scholar
  17. 17.
    Tsitsikov EN, Laouini D, Dunn IF et al. TRAF1 is a negative regulator of TNF signaling enhanced TNF signaling in TRAF1-deficient mice. Immunity 2001; 15:647–657.PubMedCrossRefGoogle Scholar
  18. 18.
    Yeh WC, Shahinian A, Speiser D et al. Early lethality, functional NF-kappaB activation and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997; 7:715–725.PubMedCrossRefGoogle Scholar
  19. 19.
    Nguyen LT, Duncan GS, Mirtsos C et al. TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses. Immunity 1999; 11:379–389.PubMedCrossRefGoogle Scholar
  20. 20.
    Kelliher MA, Grimm S, Ishida Y et al. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8:297–303.PubMedCrossRefGoogle Scholar
  21. 21.
    Yeh JH, Hsu SC, Han SH et al. Mitogen-activated protein kinase kinase antagonized fas-associated death domain protein-mediated apoptosis by induced FLICE-inhibitory protein expression. J Exp Med 1998; 188:1795–1802.PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang J, Cado D, Chen A et al. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort. 1 Nature 1998; 392:296–300.PubMedCrossRefGoogle Scholar
  23. 23.
    Varfolomeev EE, Schuchmann M, Luria V et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo,1 and DR3 and is lethal prenatally. Immunity 1998; 9:267–276.PubMedCrossRefGoogle Scholar
  24. 24.
    Li ZW, Chu W, Hu Y et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 1999; 189:1839–1845.PubMedCrossRefGoogle Scholar
  25. 25.
    Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13:135–141.PubMedCrossRefGoogle Scholar
  26. 26.
    Aggarwal BB, Shishodia S, Takada Y et al. TNF blockade: an inflammatory issue. Ernst Schering Res Found Workshop, 2006:161–186.Google Scholar
  27. 27.
    Aggarwal BB, Shishodia S, Sandur SK et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72:1605–1621.PubMedCrossRefGoogle Scholar
  28. 28.
    Komori A, Yatsunami J, Suganuma M et al. Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res 1993; 53:1982–1985.PubMedGoogle Scholar
  29. 29.
    Suganuma M, Okabe S, Marino MW et al. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 1999; 59:4516–4518.PubMedGoogle Scholar
  30. 30.
    Knight B, Yeoh GC, Husk KL et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000; 192:1809–1818.PubMedCrossRefGoogle Scholar
  31. 31.
    Digel W, Stefanic M, Schoniger W et al. Tumor necrosis factor induces proliferation of neoplastic B-cells from chronic lymphocytic leukemia. Blood 1989; 73:1242–1246.PubMedGoogle Scholar
  32. 32.
    Digel W, Schoniger W, Stefanic M et al. Receptors for tumor necrosis factor on neoplastic B-cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood 1990; 76:1607–1613.PubMedGoogle Scholar
  33. 33.
    Giri DK and Aggarwal BB. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T-cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 1998; 273:14008–14014.PubMedCrossRefGoogle Scholar
  34. 34.
    Liu RY, Fan C, Mitchell S et al. The role of type I and type II tumor necrosis factor (TNF) receptors in the ability of TNF-alpha to transduce a proliferative signal in the human megakaryoblastic leukemic cell line Mo7e. Cancer Res 1998; 58:2217–2223.PubMedGoogle Scholar
  35. 35.
    Tsukasaki K, Miller CW, Kubota T et al. Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res 2001; 61:3770–3774.PubMedGoogle Scholar
  36. 36.
    Duncombe AS, Heslop HE, Turner M et al. Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia. J Immunol 1989; 143:3828–3834.PubMedGoogle Scholar
  37. 37.
    Elbaz O and Mahmoud LA. Tumor necrosis factor and human acute leukemia. Leuk Lymphoma 1994; 12:191–195.PubMedCrossRefGoogle Scholar
  38. 38.
    Montesano R, Soulie P, Eble JA et al. Tumour necrosis factor lpha confers an invasive, transformed phenotype on mammary epithelial cells. J Cell Sci 2005; 118:3487–3500.PubMedCrossRefGoogle Scholar
  39. 39.
    Kalthoff H, Roeder C, Gieseking J et al. Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1993; 90:8972–8976.PubMedCrossRefGoogle Scholar
  40. 40.
    Schmiegel W, Roeder C, Schmielau J et al. Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci USA 1993; 90:863–867.PubMedCrossRefGoogle Scholar
  41. 41.
    Wu S, Boyer CM, Whitaker RS et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 1993; 53:1939–1944.PubMedGoogle Scholar
  42. 42.
    Woodworth CD, McMullin E, Iglesias M et al. Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci USA 1995; 92:2840–2844.PubMedCrossRefGoogle Scholar
  43. 43.
    Aggarwal BB, Schwarz L, Hogan ME et al. Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells. Cancer Res 1996; 56:5156–5164.PubMedGoogle Scholar
  44. 44.
    Goillot E, Combaret V, Ladenstein R et al. Tumor necrosis factor as an autocrine growth factor for neuroblastoma. Cancer Res 1992; 52:3194–3200.PubMedGoogle Scholar
  45. 45.
    Nabors LB, Suswam E, Huang Y et al. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Res 2003; 63:4181–4187.PubMedGoogle Scholar
  46. 46.
    Rosen EM, Goldberg ID, Liu D et al. Tumor necrosis factor stimulates epithelial tumor cell motility. Cancer Res 1991; 51:5315–5321.PubMedGoogle Scholar
  47. 47.
    Leibovich SJ, Polverini PJ, Shepard HM et al. Macrophage-induced angio genesis is mediated by tumour necrosis factor-alpha. Nature 1987; 329:630–632.PubMedCrossRefGoogle Scholar
  48. 48.
    Luo JL, Maeda S, Hsu LC et al. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNF-alpha to TRAIL-mediated tumor regression. Cancer Cell 2004; 6:297–305.PubMedCrossRefGoogle Scholar
  49. 49.
    Orosz P, Echtenacher B, Falk W et al. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 1993; 177:1391–1398.PubMedCrossRefGoogle Scholar
  50. 50.
    Kitakata H, Nemoto-Sasaki Y, Takahashi Y et al. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res 2002 62:6682–6687.PubMedGoogle Scholar
  51. 51.
    Malik ST, Naylor MS, East N et al. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 1990; 26:1031–1034.PubMedCrossRefGoogle Scholar
  52. 52.
    Orosz P, Kruger A, Hubbe M et al. Promotion of experimental liver metastasis by tumor necrosis factor. Int J Cancer 1995; 60:867–871.PubMedCrossRefGoogle Scholar
  53. 53.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487–501.PubMedCrossRefGoogle Scholar
  54. 54.
    Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 2003; 14:185–191.PubMedCrossRefGoogle Scholar
  55. 55.
    Croft M. Costimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3:609–620.PubMedCrossRefGoogle Scholar
  56. 56.
    Kim EY and Te HS. TNF type 2 receptor (p75) lowers the threshold of T-cell activation. J Immunol 2001; 167:6812–6820.PubMedGoogle Scholar
  57. 57.
    Fu YX and Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999; 17:399–433.PubMedCrossRefGoogle Scholar
  58. 58.
    Pasparakis M, Alexopoulou L, Grell M et al. Peyer’s patch organogenesis in intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proc Natl Acad Sci USA 1997; 94:6319–6323.PubMedCrossRefGoogle Scholar
  59. 59.
    Kuprash DV, Tumanov AV, Liepinsh DJ et al. Novel tumor necrosis factor-knockout mice that lack Peyer’s patches. Eur J Immunol 2005; 35:1592–1600.PubMedCrossRefGoogle Scholar
  60. 60.
    Abe K, Yarovinsky FO, Murakami T et al. Distinct contributions of TNF and LT cytokines to the development of dendritic cells in vitro and their recruitment in vivo. Blood 2003; 101:1477–1483.PubMedCrossRefGoogle Scholar
  61. 61.
    Grivennikov SI, Tumanov AV, Liepinsh DJ et al. Distinct and nonredundant in vivo functions of TNF produced by T-cells and macrophages/neutrophils: protecive and deleterious effects. Immunity 2005; 22:94–104.Google Scholar
  62. 62.
    Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499–511.PubMedCrossRefGoogle Scholar
  63. 63.
    Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6:203–208.PubMedCrossRefGoogle Scholar
  64. 64.
    Schon MP and Boehncke WH. Psoriasis. N Engl J Med 2005; 352:1899–1912.PubMedCrossRefGoogle Scholar
  65. 65.
    Okubo Y and Koga M. Peripheral blood monocytes in psoriatic patients overproduce cytokines. J Dermatol Sci 1998; 17:223–232.PubMedCrossRefGoogle Scholar
  66. 66.
    Nickoloff BJ, Karabin GD, Barker JN et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991; 138:129–140.PubMedGoogle Scholar
  67. 67.
    Gomi T, Shiohara T, Munakata T et al. Interleukin 1 alpha, tumor necrosis factor alpha and interferon gamma in psoriasis. Arch Dermatol 1991; 127:827–830.PubMedCrossRefGoogle Scholar
  68. 68.
    Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96:146–151.PubMedGoogle Scholar
  69. 69.
    Lizzul PF, Aphale A, Malaviya R et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 2005; 124:1275–1283.PubMedCrossRefGoogle Scholar
  70. 70.
    Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175:2721–2729.PubMedGoogle Scholar
  71. 71.
    Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3:521–533.PubMedCrossRefGoogle Scholar
  72. 72.
    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417–429.PubMedCrossRefGoogle Scholar
  73. 73.
    Komatsu M, Kobayashi D, Saito K et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001; 47:1297–1301.PubMedGoogle Scholar
  74. 74.
    Braegger CP, Nicholls S, Murch SH et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339:89–91.PubMedCrossRefGoogle Scholar
  75. 75.
    Breese EJ, Michie CA, Nicholls SW et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106:1455–1466.PubMedGoogle Scholar
  76. 76.
    Neurath MF, Fuss I, Pasparakis M et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997; 27:1743–1750.PubMedCrossRefGoogle Scholar
  77. 77.
    Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998; 42:477–484.PubMedGoogle Scholar
  78. 78.
    Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423:356–361.PubMedCrossRefGoogle Scholar
  79. 79.
    Saxne T, Palladino MA Jr, Heinegard D et al. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31:1041–1045.PubMedCrossRefGoogle Scholar
  80. 80.
    Chu CQ, Field M, Feldmann M et al. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34:1125–1132.PubMedCrossRefGoogle Scholar
  81. 81.
    Butler DM, Maini RN, Feldmann M et al. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alph antibody with the interleukin-1 receptor antagonist Eur Cytokine Netw 1995; 6:225–230.PubMedGoogle Scholar
  82. 82.
    Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:4025–4031.PubMedGoogle Scholar
  83. 83.
    Roos JC and Ostor AJ. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355:2046–2047; author reply 2048.PubMedCrossRefGoogle Scholar
  84. 84.
    Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr Rheumatol Rep 2002; 4:99–107.PubMedCrossRefGoogle Scholar
  85. 85.
    Medsger TA, Jr. Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol 2000; 12:545–548.PubMedCrossRefGoogle Scholar
  86. 86.
    Gruschwitz MS, Albrecht M, Vieth G et al. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. J Rheumatol 1997; 24:1936–1943.PubMedGoogle Scholar
  87. 87.
    Hasegawa M, Fujimoto M, Kikuchi K et al. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997; 24:663–665.PubMedGoogle Scholar
  88. 88.
    Majewski S, Wojas-Pelc A, Malejczyk M et al. Serum levels of soluble TNF-alpha receptor type I and the severity of systemic sclerosis. Acta Derm Venereol 1999; 79:207–210.PubMedCrossRefGoogle Scholar
  89. 89.
    Pandey JP and Takeuchi F. TNF-alpha and TNF-beta gene polymorphisms in systemic sclerosis. Hum Immunol 1999; 60:1128–1130.PubMedCrossRefGoogle Scholar
  90. 90.
    Manson JJ and Isenberg DA. The pathogenesis of systemic lupus erythematosus. Neth J Med 2003; 61:343–346.PubMedGoogle Scholar
  91. 91.
    Aringer M, Feirl E, Steiner G et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002; 11:102–108.PubMedCrossRefGoogle Scholar
  92. 92.
    Gabay C, Cakir N, Moral F et al. Circulating levels of tumor necrosis factor soluble receptor in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24:303–308.PubMedGoogle Scholar
  93. 93.
    Sieper J, Braun J, Rudwaleit M et al. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61Suppl 3:iii8–18.PubMedGoogle Scholar
  94. 94.
    Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38:499–505.PubMedCrossRefGoogle Scholar
  95. 95.
    Grom AA, Murray KJ, Luyrink L et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39:1703–1710.PubMedCrossRefGoogle Scholar
  96. 96.
    Canete JD, Llena J, Collado A et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol 1997; 36:38–42.PubMedCrossRefGoogle Scholar
  97. 97.
    Gratacos J, Collado A, Filella X et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33:927–931.PubMedCrossRefGoogle Scholar
  98. 98.
    Toussirot E, Lafforgue P, Boucraut J et al. Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 1994; 13:175–180.PubMedCrossRefGoogle Scholar
  99. 99.
    Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000; 11:212–217.PubMedCrossRefGoogle Scholar
  100. 100.
    Zoppini G, Faccini G, Muggeo M et al. Elevated plasma levels of soluble receptors of TNF-alpha and their association with smoking and microvascular complications in young adults with type 1 diabetes. J Clin Endocrinol Metab 2001; 86:3805–3808.PubMedCrossRefGoogle Scholar
  101. 101.
    Pujol-Borrell R, Todd I, Doshi M et al. HLA class II induction in human isletcells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 1987; 326:304–306.PubMedCrossRefGoogle Scholar
  102. 102.
    Mandrup-Poulsen T, Bendtzen K, Dinarello CA et al. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. J Immunol 1987; 139:4077–4082.PubMedGoogle Scholar
  103. 103.
    Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11:183–190.PubMedCrossRefGoogle Scholar
  104. 104.
    Bernard CC, Kerlero de Rosbo N. Multiple sclerosis: an autoimmune disease of multifactorial etiology. Curr Opin Immunol 1992; 4:760–765.PubMedCrossRefGoogle Scholar
  105. 105.
    Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996; 45:322–333.PubMedCrossRefGoogle Scholar
  106. 106.
    Selmaj K, Papierz W, Glabinski A et al. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 1995; 56:135–141.PubMedCrossRefGoogle Scholar
  107. 107.
    Hofman FM, Hinton DR, Johnson K et al. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170:607–612.PubMedCrossRefGoogle Scholar
  108. 108.
    Selmaj K, Raine CS, Cannella B et al. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87:949–954.PubMedCrossRefGoogle Scholar
  109. 109.
    Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325:467–472.PubMedCrossRefGoogle Scholar
  110. 110.
    Tsukada N, Matsuda M, Miyagi K et al. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 1993; 43:2679–2682.PubMedGoogle Scholar
  111. 111.
    Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:1932–1939.PubMedCrossRefGoogle Scholar
  112. 112.
    Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis. N Engl J Med 2000; 343:1586–1593.PubMedCrossRefGoogle Scholar
  113. 113.
    Hasan U. Tumour necrosis factor inhibitors—what we need to know. N Z Med J 2006; 119: U2336.PubMedGoogle Scholar
  114. 114.
    Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–1593.PubMedCrossRefGoogle Scholar
  115. 115.
    Ubriani R, Van Voorhees AS. Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases. Arch Dermatol 2007; 143:270–272.PubMedCrossRefGoogle Scholar
  116. 116.
    Corvino CL, Mamoni RL, Fagundes GZ et al. Serum interleukin-18 and soluble tumour necrosis factor receptor 2 are associated with disease severity in patients with paracoccidioidomycosis. Clin Exp Immunol 2007; 147:483–490.PubMedCrossRefGoogle Scholar
  117. 117.
    Higuchi M, Aggarwal BB. Modulation of two forms of tumor necrosis factor receptors and their cellular response by soluble receptors and their monoclonal antibodies. J Biol Chem 1992; 267:20892–20899.PubMedGoogle Scholar
  118. 118.
    Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresse NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002; 168:2644–2651.PubMedGoogle Scholar
  119. 119.
    Harousseau JL. Thalidomide in multiple myeloma: past, present and future. Future Oncol 2006; 2:577–589.PubMedCrossRefGoogle Scholar
  120. 120.
    Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 1993; 187:447–463.PubMedGoogle Scholar
  121. 121.
    Steed PM, Tansey MG, Zalevsky J et al. Ihactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 2003; 301:1895–1898.PubMedCrossRefGoogle Scholar
  122. 122.
    He MM, Smith AS, Oslob JD et al. Small-molecule inhibition of TNF-alpha. Science 2005; 310:1022–1025.PubMedCrossRefGoogle Scholar
  123. 123.
    Grzanna R, Phan P, Polotsky A et al. Ginger extract inhibits beta-amyloid peptide-induced cytokine and chemokine expression in cultured THP-1 monocytes. J Altern Complement Med 2004; 10:1009–1013.PubMedCrossRefGoogle Scholar
  124. 124.
    Matsuda H, Morikawa T, Managi H et al. Antiallergic principles from Alpinia galanga: structural requirements of phenylpropanoids for inhibition of degranulation and release of TNF-alpha and IL-4 in RBL-2H3 cells. Bioorg Med Chem Lett 2003; 13:3197–3202.PubMedCrossRefGoogle Scholar
  125. 125.
    Makris A, Thornton CE, Xu B et al. Garlic increases IL-10 and inhibits TNF-alpha and IL-6 production in endotoxin-stimulated human placental explants. Placenta 2005; 26:828–834.PubMedCrossRefGoogle Scholar
  126. 126.
    Duansak D, Somboonwong J, Patumraj S. Effects of Aloe vera on leukocyte adhesion and TNF-alpha and IL-6 levels in burn wounded rats. Clin Hemorheol Microcirc 2003; 29:239–246.PubMedGoogle Scholar
  127. 127.
    Qiu Z, Jones K, Wylie M et al. Modified Aloe barbadensis polysaccharide with immunoregulatory activity. Planta Med 2000 66:152–156.PubMedCrossRefGoogle Scholar
  128. 128.
    Kim H, Lee E, Lim T et al. Inhibitory effect of Asparagus cochinchinensis on tumor necrosis factor-alpha secretion from astrocytes. Int J Immunopharmacol 1998; 20:153–162.PubMedCrossRefGoogle Scholar
  129. 129.
    Matsuda H, Tewtrakul S, Morikawa T et al. Anti-allergic principles from Thai zedoary: structural requirements of curcuminoids for inhibition of degranulation and effect on the release of TNF-alpha and IL-4 in RBL-2H3 cells. Bioorg Med Chem 2004; 12:5891–5898.PubMedCrossRefGoogle Scholar
  130. 130.
    Lee SH, Seo GS, Sohn DH. Inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase by butein in RAW 264.7 cells. Biochem Biophys Res Commun 2004; 323:125–132.PubMedCrossRefGoogle Scholar
  131. 131.
    Lee JH, Jung HS, Giang PM et al. Blockade of nuclear factor-kappaB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera. J Pharmacol Exp Ther 2006; 316:271–278.PubMedCrossRefGoogle Scholar
  132. 132.
    Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995; 49:1551–1556.PubMedCrossRefGoogle Scholar
  133. 133.
    Shishodia S, Amin HM, Lai R et al. Curcumin (diferuloymethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005; 70:700–713.PubMedCrossRefGoogle Scholar
  134. 134.
    Gao M, Zhang J, Liu G. Effect of diphenyl dimethyl bicarboxylate on concanavalin A-induced liver injury in mice. Liver Int 2005; 25:904–912.PubMedCrossRefGoogle Scholar
  135. 135.
    Kuo YC, Tsai WJ, Meng HC et al. Immune reponses in human mesangial cells regulated by emodin from Polygonum hypoleucum Ohwi. Life Sci 2001; 68:1271–1286.PubMedCrossRefGoogle Scholar
  136. 136.
    Matsunaga K, Klein TW, Friedman H et al. Epigallocatechin gallate, a potential immunomodulatory agent of tea components, diminishes cigarette smoke condensate-induced suppression of antiLegionella pneumophila activity and cytokine responses of alveolar macrophages. Clin Diagn Lab Immunol 2002; 9:864–871.PubMedGoogle Scholar
  137. 137.
    Lin AH, Fang SX, Fang JG et al. [Studies on anti-endotoxin activity of F022 from Radix Isatidis]. Zhongguo Zhong Yao Za Zhi 2002; 27:439–442.PubMedGoogle Scholar
  138. 138.
    Nie ZG, Peng SY, Wang WJ. [Effects of ginkgolide B on lipopolysaccharide-induced TNF-alpha production in mouse peritoneal macrophages and NF-kappaB activation in rat pleural polymorphonuclear leukocytes]. Yao Xue Xue Bao 2004; 39:415–418.PubMedGoogle Scholar
  139. 139.
    Wadsworth TL, McDonald TL, Koop DR. Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced signaling pathways involved in the release of tumor necrosis factor-alpha. Biochem Pharmacol 2001; 62:963–974.PubMedCrossRefGoogle Scholar
  140. 140.
    Abuarqoub H, Foresti R, Green CJ et al. Heme oxygenase-1 mediates the anti-inflammatory actions of 2′-hydroxychalcone in RAW 264.7 murine macrophages. Am J Physiol Cell Physiol 2006; 290: C1092–1099.PubMedCrossRefGoogle Scholar
  141. 141.
    Ban HS, Suzuki K, Lim SS et al. Inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase and tumor necrosis factor-alpha by 2′-hydroxychalcone derivatives in RAW 264.7 cells. Biochem Pharmacol 2004; 67:1549–1557.PubMedCrossRefGoogle Scholar
  142. 142.
    Ojo-Amaize EA, Kapahi P, Kakkanaiah VN et al. Hypoestoxide, a novel anti-inflammatory natural diterpene, inhibits the activity of IkappaB kinase. Cell Immunol 2001; 209:149–157.PubMedCrossRefGoogle Scholar
  143. 143.
    Kang OH, Choi YA, Park HJ et al. Inhibition of trypsin-induced mastcell activation by water fraction of Lonicera japonica. Arch Pharm Res 2004; 27:1141–1146.PubMedCrossRefGoogle Scholar
  144. 144.
    Cho JY, Park J, Yoo ES et al. Inhibitory effect of lignans from the rhizomes of Coptis japonica var. dissecta on tumor necrosis factor-alpha production in lipopolysaccharide-stimulated RAW264.7 cells. Arch Pharm Res 1998; 21:12–16.PubMedGoogle Scholar
  145. 145.
    Ju HK, Moon TC, Lee E et al. Inhibitory effects of a new iridoid, patridoid II and its isomers, on nitric oxide and TNF-alpha production in cultured murine macrophages. Planta Med 2003; 69:950–953.PubMedCrossRefGoogle Scholar
  146. 146.
    Liu L, Ning ZQ, Shan S et al. Phthalide Lactones from Ligusticum chuanxiong inhibit lipopolysac-charide-induced TNF-alpha production and TNF-alpha-mediated NF-kappaB Activation. Planta Med 2005; 71:808–813.PubMedCrossRefGoogle Scholar
  147. 147.
    Ishii R, Horie M, Saito K et al. Inhibition of lipopolysaccharide-induced pro-inflammatory cytokine expression via suppression of nuclear factor-kappaB activation by Mallotus japonicus phloroglucinol derivatives. Biochim Biophys Acta 2003; 1620:108–118.PubMedGoogle Scholar
  148. 148.
    Wang C, Schuller Levis GB, Lee EB et al. Platycodin D and D3 isolated from the root of Platycodon grandiflorum modulate the production of nitric oxide and secretion of TNF-alpha in activated RAW 264.7 cells. Int Immunopharmacol 2004; 4:1039–1049.PubMedCrossRefGoogle Scholar
  149. 149.
    Punzon C, Alcaide A, Fresno M. In vitro anti-inflammatory activity of Phlebodium decumanum. Modulation of tumor necrosis factor and soluble TNF receptors. Int Immunopharmacol 2003; 3:1293–1299.PubMedCrossRefGoogle Scholar
  150. 150.
    Kiemer AK, Hartung T, Huber C et al. Phyllanthus amarus has anti-inflammatory potential by inhibition of iNOS, COX-2 and cytokines via the NF-kappaB pathway. J Hepatol 2003; 38:289–297.PubMedCrossRefGoogle Scholar
  151. 151.
    Bi XL, Yang JY, Dong YX et al. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int Immunopharmacol 2005; 5:185–193.PubMedCrossRefGoogle Scholar
  152. 152.
    Perrone A, Plaza A, Ercolino SF et al. 14,15-secopregnane derivatives from the leaves of Solenostemma argel. J Nat Prod 2006; 69:50–54.PubMedCrossRefGoogle Scholar
  153. 153.
    Xi X, Mukhtar H, Agarwal R. novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF-alpha. Biochem Biophys Res Commun 1997; 239:334–339.CrossRefGoogle Scholar
  154. 154.
    Abad MJ, Bermejo P, Alvarez M et al. Flavonoids and a sesquiterpene lactone from Tanacetum microphyllum inhibit anti-inflammatory mediators in LPS-stimulated mouse peritoneal macrophages. Planta Med 2004; 70:34–38.PubMedCrossRefGoogle Scholar
  155. 155.
    Kim HM, Shin HY, Lim KH et al. Taraxacum officinale inhibits tumor necrosis factor-alpha production from rat astrocytes. Immunopharmacol Immunotoxicol 2000; 22:519–530.PubMedCrossRefGoogle Scholar
  156. 156.
    Verhoeckx KC, Korthout HA, van Meeteren-Kreikamp AP et al. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 2006; 6:656–665.PubMedCrossRefGoogle Scholar
  157. 157.
    Ramiro E, Franch A, Castellote C et al. Effect of Theobroma cacao flavonoids on immune activation of a lymphoid cell line. Br J Nutr 2005; 93:859–866.PubMedCrossRefGoogle Scholar
  158. 158.
    Piscoya J, Rodriguez Z, Bustamante SA et al. Efficacy and safety of freeze-dried cat’s claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res 2001; 50:442–448.PubMedCrossRefGoogle Scholar
  159. 159.
    Hua KF, Hsu HY, Su YC et al. Study on the antiinflammatory activity of methanol extract from seagrass Zostera japonica. J Agric Food Chem 2006; 54:306–311.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Gautam Sethi
    • 1
  • Bokyung Sung
    • 1
  • Ajaikumar B. Kunnumakkara
    • 1
  • Bharat B. Aggarwal
    • 1
  1. 1.Cytokine Research Laboratory, Department of Experimental TherapeuticsThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations